Sculptor Capital’s Anavex Life Sciences AVXL Stock Holding History

Sculptor Capital’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-155,900	Closed	-$555K	–	377
2025 Q4	$555K	Hold	155,900	–	–	0.01%	296
2025 Q3	$1.39M	Hold	155,900	–	–	0.02%	242
2025 Q2	$1.44M	Buy	+155,900	New	+$1.33M	0.02%	233
2025 Q1	–	Sell	-371,400	Closed	-$3.99M	–	334
2024 Q4	$3.99M	Hold	371,400	–	–	0.05%	165
2024 Q3	$2.11M	Hold	371,400	–	–	0.04%	170
2024 Q2	$1.57M	Hold	371,400	–	–	0.03%	150
2024 Q1	$1.89M	Buy	+371,400	New	+$2.09M	0.04%	139

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sculptor Capital's AVXL Position: Q1 2026 in Review

Sculptor Capital sold out of Anavex Life Sciences (AVXL) in Q1 2026, closing a stake of 155,900 shares — an estimated $555K sold.

Sculptor Capital first reported a position in AVXL in Q1 2024 and held it in 7 quarters. The position peaked at $3.97M in Q4 2024. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

Sculptor Capital reported no remaining Anavex Life Sciences position as of Q1 2026 after selling out during the quarter.
Sculptor Capital sold 155,900 Anavex Life Sciences shares in Q1 2026, an estimated $555K.
Sculptor Capital first reported a position in Anavex Life Sciences in Q1 2024 and held it in 7 quarters.
Sculptor Capital's Anavex Life Sciences position peaked at $3.97M in Q4 2024.
190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.